Atlas Trials

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

Clinical trial NCT05879276 · RECRUITING

Trial details

NCT number
NCT05879276
Sponsor
Central Hospital, Nancy, France
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Cardiogenic Shock
Start date
2024-12-16
Primary completion
2027-03-16
Enrollment
164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.